California and Shanghai-based Terns Pharmaceuticals Inc has closed an $80-million Series B funding round co-led by Vivo Capital and OrbiMed, according to an announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
